MetaCap

Benitec Biopharma (BNTC) vs Relmada Therapeutics (RLMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Relmada Therapeutics (RLMD) has outperformed Benitec Biopharma (BNTC) over the past year, losing 38.6% versus a loss of 40.3%. Over five years, BNTC leads with a -85.7% price change compared with -86.1% for RLMD. Benitec Biopharma is the larger company by market cap ($285.9 million vs $279.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTC-40.31%RLMD-38.64%
+90%+22%-47%
Nov 21, 20251 yearNov 20, 2026
BNTC-85.45%RLMD-87.15%
+91%-9%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTC versus RLMD key metrics
MetricBNTCRLMD
Share price$7.92$2.62
Market cap$285.88M$279.54M
1-day change-2.76%-15.76%
YTD return-41.24%-45.76%
1-year return-40.31%-38.64%
5-year return-85.67%-86.09%
EPS (TTM)$-1.02$-0.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-45.55M$-57.39M
52-week high$14.39$8.00
52-week low$7.72$2.60
Distance from 52-week high-45.00%-67.25%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+200.06%+310.31%
Average volume174.01K1.45M
Shares outstanding36.12M106.69M
Employees2417
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Benitec Biopharma

BNTC stock →

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.

Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees

About Relmada Therapeutics

RLMD stock →

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

BNTC vs RLMD FAQ

Which is bigger, Benitec Biopharma or Relmada Therapeutics?

Benitec Biopharma (BNTC) is larger, with a market capitalization of $285.88M compared with $279.54M for Relmada Therapeutics (RLMD).

Which stock has performed better over the past year, BNTC or RLMD?

RLMD returned -38.64% over the past 12 months, compared with -40.31% for BNTC (price return, excluding dividends). Past performance does not predict future results.

Are Benitec Biopharma and Relmada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons